Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Yue Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0864-8990; OpenAlex author ID A5005471950. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper

Papers 7

  1. CXCL1-CXCR2 signaling mediates the activation of microglia in the nucleus tractus solitarii to promote pancreatic cancer-induced pain. Co-author DOI 10.1016/j.bbi.2024.11.016↗
  2. Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1002/advs.202406714↗
  3. Contrast-enhanced CT radiomics combined with multiple machine learning algorithms for preoperative identification of lymph node metastasis in pancreatic ductal… Co-author DOI 10.3389/fonc.2024.1342317↗
  4. Comparison of multiple machine learning models for predicting prognosis of pancreatic ductal adenocarcinoma based on contrast-enhanced CT radiomics and clinica… Co-author DOI 10.3389/fonc.2024.1419297↗
  5. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05715-1↗
  6. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05939-1↗
  7. METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. Co-author DOI 10.3389/fonc.2022.962204↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangeng Weng · 5 shared papers, 2022–2024 · strength 1.00
  2. Zhenyun Guo · 3 shared papers, 2022–2023 · strength 0.55
  3. Xiang Zhang · 3 shared papers, 2022–2023 · strength 0.55
  4. Chengjie Lin · 3 shared papers, 2022–2023 · strength 0.55
  5. Guozhong Liu · 2 shared papers, 2024 · strength 0.45
  6. Shihui Lai · 2 shared papers, 2023 · strength 0.39
  7. Jingdun Xie · 1 shared paper, 2025 · strength 0.22
  8. Kang Chen · 1 shared paper, 2025 · strength 0.22
  9. Yanqun Zhang · 1 shared paper, 2025 · strength 0.22
  10. Yan Wang · 1 shared paper, 2023 · strength 0.19
  11. Yin-Hao Shi · 1 shared paper, 2024 · strength 0.18
  12. Ying‐Qin Zhu · 1 shared paper, 2024 · strength 0.18
  13. Mingjian Ma · 1 shared paper, 2024 · strength 0.18
  14. Zhide Liu · 1 shared paper, 2024 · strength 0.18
  15. Jie‐Qin Wang · 1 shared paper, 2024 · strength 0.18
  16. Chen‐Song Huang · 1 shared paper, 2024 · strength 0.18
  17. Xiao-Yu Yin · 1 shared paper, 2024 · strength 0.18
  18. Xi‐Tai Huang · 1 shared paper, 2024 · strength 0.18
  19. Yun Zhong · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.